Close Menu

Bio-Rad

The firm is using ddPCR to support testing 3,000 samples per day with a turnaround time of approximately 24 hours

The overall revenue decrease was buoyed by 19 percent year-over-year growth in Life Science segment revenues due to strong PCR-related sales.

According to the registry's first dataset, more than 65 million tests have been manufactured and shipped across the US.

Of the 28 companies in the index, 18 firms saw their stock prices increase, while 10 firms' share prices decreased. 

The reimbursement rates for the most commonly performed SARS-CoV-2 serologic tests are $42.13 and $45.23, depending on the billing code used.

The listing enables assay developers and testing labs in the US to access the instrument for COVID-19 testing, the firm said.

Bio-Rad said it is withdrawing its previously issued annual revenue guidance given the uncertainties regarding the duration and impact of the COVID-19 pandemic.

The triplex assay can be used on the firm's QX200 or QXDx Droplet Digital PCR systems to process 93 patient samples per run.

The assay is designed to detect all human antibodies against SARS-CoV-2, including immunoglobulin M, immunoglobulin A, and immunoglobulin G.

Pages